Compare Enovix Corporation (ENVX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Illumina, Inc. — how do they compare? Enovix Corporation trades at $4.78 (market cap $1.06B), while Illumina, Inc. trades at $190.93 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 27.5× Enovix Corporation's market cap, and Illumina, Inc. is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ENVX | ILMN | |
|---|---|---|
Market Cap | $1.06B | $29.12B |
Sector | Technology | Health |
52-Week High | $13.19 | $205.10 |
52-Week Low | $3.68 | $91.00 |
Enterprise Value | $1.07B | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX is trading at $4.825, up 3.99% with strong analyst support (75% buy ratings) and a $12.38 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics, with recent earnings beats and strategic leadership appointments driving optimism. Revenue growth remains modest at $31.82M for 2025, but significant cash burn and negative margins highlight execution risks as the company scales battery production.
The outlook balances high growth potential in advanced battery technology against substantial financial losses. Investment opportunity lies in market leadership in silicon-anode batteries and recent operational improvements, while risks include persistent cash burn and competitive pressures in the evolving energy storage sector.
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
